These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 19607884)
1. Central cannabinoid signaling mediating food intake: a pharmacological-challenge magnetic resonance imaging and functional histology study in rat. Dodd GT; Stark JA; McKie S; Williams SR; Luckman SM Neuroscience; 2009 Nov; 163(4):1192-200. PubMed ID: 19607884 [TBL] [Abstract][Full Text] [Related]
2. The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice. Dodd GT; Mancini G; Lutz B; Luckman SM J Neurosci; 2010 May; 30(21):7369-76. PubMed ID: 20505104 [TBL] [Abstract][Full Text] [Related]
3. Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats. Järbe TU; DiPatrizio NV Behav Pharmacol; 2005 Sep; 16(5-6):373-80. PubMed ID: 16148441 [TBL] [Abstract][Full Text] [Related]
4. Localization and phenotypic characterization of brainstem neurons activated by rimonabant and WIN55,212-2. Jelsing J; Galzin AM; Guillot E; Pruniaux MP; Larsen PJ; Vrang N Brain Res Bull; 2009 Mar; 78(4-5):202-10. PubMed ID: 19038314 [TBL] [Abstract][Full Text] [Related]
5. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells. Chiba T; Ueno S; Obara Y; Nakahata N J Pharm Pharmacol; 2011 May; 63(5):636-47. PubMed ID: 21492165 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233. Dhawan J; Deng H; Gatley SJ; Makriyannis A; Akinfeleye T; Bruneus M; Dimaio AA; Gifford AN Synapse; 2006 Aug; 60(2):93-101. PubMed ID: 16715483 [TBL] [Abstract][Full Text] [Related]
10. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510 [TBL] [Abstract][Full Text] [Related]
11. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. Ahn KH; Mahmoud MM; Kendall DA J Biol Chem; 2012 Apr; 287(15):12070-82. PubMed ID: 22343625 [TBL] [Abstract][Full Text] [Related]
12. Benzophenanthridine alkaloid, piperonyl butoxide and (S)-methoprene action at the cannabinoid-1 receptor (CB1-receptor) pathway of mouse brain: Interference with [(3)H]CP55940 and [(3)H]SR141716A binding and modification of WIN55212-2-dependent inhibition of synaptosomal l-glutamate release. Dhopeshwarkar AS; Nicholson RA Eur J Pharmacol; 2014 Jan; 723():431-41. PubMed ID: 24211785 [TBL] [Abstract][Full Text] [Related]
13. Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant. Martín-García E; Burokas A; Martín M; Berrendero F; Rubí B; Kiesselbach C; Heyne A; Gispert JD; Millán O; Maldonado R J Neurochem; 2010 Mar; 112(5):1338-13351. PubMed ID: 20028452 [TBL] [Abstract][Full Text] [Related]
14. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764 [TBL] [Abstract][Full Text] [Related]
15. Activation of brain-type cannabinoid receptors interferes with preimplantation mouse embryo development. Yang ZM; Paria BC; Dey SK Biol Reprod; 1996 Oct; 55(4):756-61. PubMed ID: 8879486 [TBL] [Abstract][Full Text] [Related]
16. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Horswill JG; Bali U; Shaaban S; Keily JF; Jeevaratnam P; Babbs AJ; Reynet C; Wong Kai In P Br J Pharmacol; 2007 Nov; 152(5):805-14. PubMed ID: 17592509 [TBL] [Abstract][Full Text] [Related]
17. Cannabinoid-induced tolerance is associated with a CB1 receptor G protein coupling switch that is prevented by ultra-low dose rimonabant. Paquette JJ; Wang HY; Bakshi K; Olmstead MC Behav Pharmacol; 2007 Dec; 18(8):767-76. PubMed ID: 17989514 [TBL] [Abstract][Full Text] [Related]
18. Leptin receptor deficiency is associated with upregulation of cannabinoid 1 receptors in limbic brain regions. Thanos PK; Ramalhete RC; Michaelides M; Piyis YK; Wang GJ; Volkow ND Synapse; 2008 Sep; 62(9):637-42. PubMed ID: 18563836 [TBL] [Abstract][Full Text] [Related]
19. Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior. Duarte C; Alonso R; Bichet N; Cohen C; Soubrié P; Thiébot MH Neuropsychopharmacology; 2004 May; 29(5):911-20. PubMed ID: 14694354 [TBL] [Abstract][Full Text] [Related]
20. Central functional response to the novel peptide cannabinoid, hemopressin. Dodd GT; Worth AA; Hodkinson DJ; Srivastava RK; Lutz B; Williams SR; Luckman SM Neuropharmacology; 2013 Aug; 71():27-36. PubMed ID: 23542442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]